CardioDx Announces Participation at Upcoming Investor Conferences
Lazard Capital Markets Healthcare Conference 2011
Piper Jaffray Healthcare Conference 2011
PALO ALTO, Calif.--CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced that Chief Executive Officer David Levison will participate at two upcoming investor conferences.
- On Wednesday, November 16, 2011 at 8:00 a.m. ET, Levison will present at the Lazard Capital Markets 8th Annual Healthcare Conference at The Pierre Hotel in New York, NY.
- On Tuesday, November 29, 2011 at 12:10 p.m. ET, Levison will present at the 23rd Annual Piper Jaffray Health Care Conference at The New York Palace Hotel in New York, NY.
Both presentations will feature an overview of the company and of Corus® CAD, the first and only clinically validated gene expression test for obstructive coronary artery disease.
Corus CAD is a decision-making tool that can help primary care clinicians and cardiologists rule out obstructive coronary artery disease as the cause of a nondiabetic patient's symptoms. The test involves a routine blood draw conveniently administered in the clinician’s office, and does not expose patients to risks of radiation or imaging agent intolerance. It is the only sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women. Corus CAD has now been used to assess more than 20,000 patients.
Findings from the PREDICT validation study of the Corus CAD gene expression test were published in 2010 in the Annals of Internal Medicine, the journal of the American College of Physicians. New data related to Corus CAD will be presented at the American Heart Association Scientific Sessions 2011 conference taking place November 12-16 in Orlando, Fla., including an oral presentation of the results of the COMPASS trial. COMPASS represents a third independent validation study for Corus CAD, comparing the test to myocardial perfusion imaging (MPI) in a population of stable symptomatic patients with suspected obstructive coronary artery disease.
The test has been honored as a winner of The Wall Street Journal’s prestigious Technology Innovation Awards and one of TIME’s Top Ten Medical Breakthroughs.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.